Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 9 » Issue 1

Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trials

Authors Rennard SI, Sun SX, Tourkodimitris S, Rowe P, Goehring UM, Bredenbröker D, Calverley PM

Received 11 October 2013

Accepted for publication 16 December 2013

Published 24 June 2014 Volume 2014:9(1) Pages 657—673

DOI https://doi.org/10.2147/COPD.S55738

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Stephen I Rennard,1 Shawn X Sun,2 Stavros Tourkodimitris,2 Paul Rowe,2 Udo M Goehring,3 Dirk Bredenbröker,3 Peter M A Calverley4

1Division of Pulmonary, Critical Care, Sleep and Allergy, University of Nebraska Medical Center, Omaha, NE, USA; 2Forest Research Institute, Jersey City, NJ, USA; 3Takeda Pharmaceuticals International GmbH, Zurich, Switzerland; 4Department of Clinical Science, University of Liverpool, Liverpool, UK

Purpose: Breathlessness is a predominant symptom of chronic obstructive pulmonary disease (COPD), making it a valuable outcome in addition to lung function to assess treatment benefit. The phosphodiesterase-4 inhibitor roflumilast has been shown to provide small but significant improvements in dyspnea, as measured by the transition dyspnea index (TDI), in two 1-year studies in patients with severe to very severe COPD.
Patients and methods: To provide a more comprehensive assessment of the impact of roflumilast on dyspnea, post hoc analyses of four 1-year roflumilast studies (M2-111, M2-112, M2-124, and M2-125) in patients with moderate to very severe COPD were conducted.
Results: In this pooled analysis (N=5,595), roflumilast significantly improved TDI focal scores versus placebo at week 52 (treatment difference, 0.327; P<0.0001). Roflumilast was associated with significantly greater TDI responders and significantly fewer TDI deteriorators (≥1-unit increase or decrease from baseline, respectively) versus placebo at week 52 (P<0.01, both); these significant differences were apparent by week 8 and maintained until study end (P<0.05, all). At study end, the postbronchodilator forced expiratory volume in 1 second improvement in TDI responders was significantly greater with roflumilast versus placebo (P<0.05). Similar to the overall population, improvements in TDI focal scores at week 52 were small but consistently significant over placebo in patients with chronic bronchitis, regardless of exacerbation history, concomitant treatment with short-acting muscarinic antagonists or long-acting β2-agonists, or pretreatment with inhaled corticosteroids.
Conclusion: This analysis shows that patients treated with roflumilast to reduce exacerbation risk may also experience small but significant improvements in dyspnea, with accompanying improvements in lung function.

Keywords: phosphodiesterase-4 inhibitor, breathlessness, lung function, subgroup analyses

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Anti-inflammatory effects of budesonide in human lung fibroblasts are independent of histone deacetylase 2

Wang X, Nelson A, Weiler ZM, Patil A, Sato T, Kanaji N, Nakanishi M, Michalski J, Farid M, Basma H, LeVan TD, Miller-Larsson A, Wieslander E, Muller KC, Holz O, Magnussen H, Rabe KF, Liu X, Rennard SI

Journal of Inflammation Research 2013, 6:109-119

Published Date: 20 August 2013

Effect of budesonide on fibroblast-mediated collagen gel contraction and degradation

Fang Q, Schulte NA, Kim H, Kobayashi T, Wang X, Miller-Larsson A, Wieslander E, Toews ML, Liu X, Rennard SI

Journal of Inflammation Research 2013, 6:25-33

Published Date: 27 February 2013

Readers of this article also read:

Vitamin D deficiency is associated with impaired disease control in asthma–COPD overlap syndrome patients

Odler B, Ivancsó I, Somogyi V, Benke K, Tamási L, Gálffy G, Szalay B, Müller V

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:2017-2025

Published Date: 24 September 2015

Supported self-management for patients with COPD who have recently been discharged from hospital: a systematic review and meta-analysis

Majothi S, Jolly K, Heneghan NR, Price MJ, Riley RD, Turner AM, Bayliss SE, Moore DJ, Singh SJ, Adab P, Fitzmaurice DA, Jordan RE

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:853-867

Published Date: 29 April 2015

Rescuing compound bioactivity in a secondary cell-based screening by using γ-cyclodextrin as a molecular carrier

Claveria-Gimeno R, Vega S, Grazu V, de la Fuente JM, Lanas A, Velazquez-Campoy A, Abian O

International Journal of Nanomedicine 2015, 10:2249-2259

Published Date: 19 March 2015

Gum arabic-coated radioactive gold nanoparticles cause no short-term local or systemic toxicity in the clinically relevant canine model of prostate cancer

Axiak-Bechtel SM, Upendran A, Lattimer JC, Kelsey J, Cutler CS, Selting KA, Bryan JN, Henry CJ, Boote E, Tate DJ, Bryan ME, Katti KV, Kannan R

International Journal of Nanomedicine 2014, 9:5001-5011

Published Date: 28 October 2014

Functionalization of ethylene vinyl acetate with antimicrobial chlorhexidine hexametaphosphate nanoparticles

Wood NJ, Maddocks SE, Grady HJ, Collins AM, Barbour ME

International Journal of Nanomedicine 2014, 9:4145-4152

Published Date: 27 August 2014

Sulfatide-containing lipid perfluorooctylbromide nanoparticles as paclitaxel vehicles targeting breast carcinoma

Li X, Qin F, Yang L, Mo LQ, Li L, Hou LB

International Journal of Nanomedicine 2014, 9:3971-3985

Published Date: 18 August 2014

Self-assembled nanoparticles based on the c(RGDfk) peptide for the delivery of siRNA targeting the VEGFR2 gene for tumor therapy

Liu L, Liu X, Xu Q, Wu P, Zuo X, Zhang J, Deng H, Wu Z, Ji A

International Journal of Nanomedicine 2014, 9:3509-3526

Published Date: 29 July 2014

Interleukin-6 and interleukin-8 blood levels’ poor association with the severity and clinical profile of ex-smokers with COPD

Moraes MR, da Costa AC, Corrêa KS, Junqueira-Kipnis AP, Rabahi MF

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:735-743

Published Date: 29 July 2014

Enhanced antifungal efficacy of tebuconazole using gated pH-driven mesoporous nanoparticles

Mas N, Galiana I, Hurtado S, Mondragón L, Bernardos A, Sancenón F, Marcos MD, Amorós P, Abril-Utrillas N, Martínez-Máñez R, Murguía JR

International Journal of Nanomedicine 2014, 9:2597-2606

Published Date: 23 May 2014